Samuel V Agresta

USPTO Granted Patents = 14 (Patent Applications = 9)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 57(Granted Patents)

Company Filing History:

11 out of 96

Agios Pharmaceuticals, Inc.

patents

2 out of 52

Merrimack Pharmaceuticals, Inc.

Servier Pharmaceuticals LLC

patents

where one patent can have more than one assignee

Years Active: 2016-2022

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11419859 - Combination therapy for treating malignancies (2022-08-23),

2. 11234976 - Methods of using pyruvate kinase activators (2022-02-01),

3. 10980788 - Therapy for treating malignancies (2021-04-20),

4. 10905692 - Combination therapy for treating malignancies (2021-02-02),

5. 10730854 - Therapeutically active compounds and their methods of use (2020-08-04),

6. 10695352 - Combination therapy for treating malignancies (2020-06-30),

7. 10653710 - Combination therapy for treating malignancies (2020-05-19),

8. 10105369 - Therapeutically active compounds and their methods of use (2018-10-23),

9. 10093654 - Therapeutically active compounds and their methods of use (2018-10-09),

10. 9968694 - Compositions and methods for non-invasive imaging (2018-05-15),

11. 9889137 - Therapeutically active compounds and their methods of use (2018-02-13),

12. 9738625 - Therapeutically active compounds and their methods of use (2017-08-22),

13. 9694013 - Therapeutically active compounds and their methods of use (2017-07-04),

14. 9511155 - Compositions and methods for non-invasive imaging (2016-12-06),

Title: The Innovative Contributions of Samuel V Agresta

Introduction

Samuel V Agresta is a prominent inventor based in Lexington, MA, known for his significant contributions to the field of medical therapies. With a total of 14 patents to his name, Agresta has made remarkable strides in developing innovative treatments for various malignancies.

Latest Patents

Among his latest patents is a groundbreaking combination therapy for treating acute myelogenous leukemia (AML) in patients with an IDH1 mutation. This patent outlines methods and compositions that utilize an inhibitor of a mutant IDH1 enzyme in conjunction with cytarabine and doxorubicin or idarubicin as induction therapy. Additionally, it includes the use of cytarabine or a combination of mitoxantrone and etoposide as consolidation therapy. Another notable patent describes methods for using pyruvate kinase activators, showcasing Agresta's commitment to advancing cancer treatment methodologies.

Career Highlights

Agresta has had a distinguished career, working with leading pharmaceutical companies such as Agios Pharmaceuticals, Inc. and Merrimack Pharmaceuticals, Inc. His work has focused on developing innovative therapies that address critical health challenges, particularly in oncology.

Collaborations

Throughout his career, Agresta has collaborated with esteemed colleagues, including Hua Yang and Chong-Hui Gu. These partnerships have fostered a collaborative environment that enhances the development of effective medical treatments.

Conclusion

Samuel V Agresta's contributions to medical innovation, particularly in cancer therapies, underscore his role as a leading inventor in the field. His patents reflect a dedication to improving patient outcomes through advanced therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.